Endocannabinoid
Resource Center
Recent Articles
Cannabis for Post-traumatic Stress Disorder Therapy
A new study shows that cannabis may be helpful to address the effects of post-traumatic stress disorder (PTSD). According to health survey data collected by
Mayo Clinicians’ Guide to Cannabidiol and Hemp Oil
In this summary-scientific review from Mayo Clinical Proceedings, the researchers provide an overview of the scientific work on cannabidiol and hemp oil and the distinction
Webinar: The Most Common Therapeutic Applications of CBD
Do you have questions about the therapeutic applications of CBD? We thought so. Preclinical and clinical studies suggest that cannabidiol (CBD) has broad therapeutic value.
FDA Announces Early Fall Cannabidiol Hearings and Clarifies Commitment to Enforcement
The FDA announced that it will host further cannabidiol hearing on the regulatory structure of CBD products in the early fall. The news was embedded
Medicinal Cannabis Reduces or Ends Seizures in Children with Severe, Drug-resistant Epilepsy
Medicinal cannabis oil containing both cannabidiol (CBD) and a small amount of THC can reduce or end seizures in children with severe, drug-resistant epilepsy, a
Could the Endocannabinoid System Offer a New Treatment Target for Obsessive Compulsive Disorder?
The disabling condition of obsessive-compulsive disorder (OCD) affects about 2–3% of people worldwide. Evidence suggests that abnormalities in cortico-striatal-thalamic-cortical circuitry and specific gene variants contribute
International Cannabinoid Research Society (ICRS) Names Cannabis and Cannabinoid Research Its Official Journal
New Rochelle, NY, May 7, 2019—Cannabis and Cannabinoid Research (CCR) is extremely excited to announce that the International Cannabinoid Research Society (ICRS) has named CCR
Four Articles: Cannabis and Cannabinoid Use in Palliative Care, Open Access until May 6, 2019
Patients are aware that medical cannabis and cannabinoid derivatives are available to treat pain and symptoms. However, the medical literature to guide palliative medicine physicians
Interaction of Neurotransmitters and Neurochemicals with Lymphocytes, including the Endocannabinoid System
Neurotransmitters and neurochemicals can act on lymphocytes by binding to receptors expressed by lymphocytes. This review describes lymphocyte expression of receptors for a selection of
Safety and Efficacy of Medical Cannabis in Elderly Patients: A Retrospective Review in a Neurological Outpatient Setting
As more states legalize medical cannabis, clinicians are seeking more information on how it may affect elderly populations for chronic conditions associated with aging. In
New Study on the Endocannabinoid System and Stroke
To gain access to this article and the rest of our extensive database of full-text articles, please register below or log in here.Existing Users Log
FDA Commissioner Scott Gottlieb, M.D. on Public Hearing for Cannabis-containing and Cannabis-derived Products
Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to advance agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products In
Cannabis for Post-traumatic Stress Disorder Therapy
A new study shows that cannabis may be helpful to address the effects of post-traumatic stress disorder (PTSD). According to health survey data collected by
Mayo Clinicians’ Guide to Cannabidiol and Hemp Oil
In this summary-scientific review from Mayo Clinical Proceedings, the researchers provide an overview of the scientific work on cannabidiol and hemp oil and the distinction
Webinar: The Most Common Therapeutic Applications of CBD
Do you have questions about the therapeutic applications of CBD? We thought so. Preclinical and clinical studies suggest that cannabidiol (CBD) has broad therapeutic value.
FDA Announces Early Fall Cannabidiol Hearings and Clarifies Commitment to Enforcement
The FDA announced that it will host further cannabidiol hearing on the regulatory structure of CBD products in the early fall. The news was embedded
Medicinal Cannabis Reduces or Ends Seizures in Children with Severe, Drug-resistant Epilepsy
Medicinal cannabis oil containing both cannabidiol (CBD) and a small amount of THC can reduce or end seizures in children with severe, drug-resistant epilepsy, a
Could the Endocannabinoid System Offer a New Treatment Target for Obsessive Compulsive Disorder?
The disabling condition of obsessive-compulsive disorder (OCD) affects about 2–3% of people worldwide. Evidence suggests that abnormalities in cortico-striatal-thalamic-cortical circuitry and specific gene variants contribute
International Cannabinoid Research Society (ICRS) Names Cannabis and Cannabinoid Research Its Official Journal
New Rochelle, NY, May 7, 2019—Cannabis and Cannabinoid Research (CCR) is extremely excited to announce that the International Cannabinoid Research Society (ICRS) has named CCR
Four Articles: Cannabis and Cannabinoid Use in Palliative Care, Open Access until May 6, 2019
Patients are aware that medical cannabis and cannabinoid derivatives are available to treat pain and symptoms. However, the medical literature to guide palliative medicine physicians
Interaction of Neurotransmitters and Neurochemicals with Lymphocytes, including the Endocannabinoid System
Neurotransmitters and neurochemicals can act on lymphocytes by binding to receptors expressed by lymphocytes. This review describes lymphocyte expression of receptors for a selection of
Safety and Efficacy of Medical Cannabis in Elderly Patients: A Retrospective Review in a Neurological Outpatient Setting
As more states legalize medical cannabis, clinicians are seeking more information on how it may affect elderly populations for chronic conditions associated with aging. In
New Study on the Endocannabinoid System and Stroke
To gain access to this article and the rest of our extensive database of full-text articles, please register below or log in here.Existing Users Log
FDA Commissioner Scott Gottlieb, M.D. on Public Hearing for Cannabis-containing and Cannabis-derived Products
Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to advance agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products In
